#Germany #Fremont #Alamar Biosciences #DZNE #Rhineland Study

Alamar Biosciences and DZNE: A Groundbreaking Partnership in Proteomics

Alamar Biosciences, renowned for developing precision proteomics solutions geared towards early disease detection, has announced a strategic partnership with the German Center for Neurodegenerative Diseases (DZNE). This collaboration aims to implement advanced proteomic profiling methodologies in the Rhineland Study, regarded as one of the world’s most comprehensive cohort studies focusing on aging and neurodegeneration.

The partnership will leverage the NULISAseq™ 120 panel for central nervous system diseases alongside the NULISAseq™ 250 inflammatory panel across an impressive cohort of 23,000 longitudinal plasma samples. This ambitious project seeks to enhance the understanding of molecular biomarkers associated with healthy aging and neurodegenerative processes.

Exploring the Aging Brain

Professor Monique Breteler, Director of Population Health Sciences at DZNE and the principal investigator for the Rhineland Study, emphasized the importance of combining advanced technology with meticulously characterized cohorts to comprehend the mechanisms of aging and dementia. She stated, “Incorporating Alamar’s comprehensive panels into our research opens up new avenues for identifying molecular signs of brain aging.”

The DZNE Rhineland Study, an ongoing large-scale population cohort study, aims to identify factors contributing to healthy aging and the development of neurodegenerative diseases throughout a person’s life. Utilizing the NULISAseq 120 panel, researchers can measure hundreds of brain-associated proteins from their minimal presence in blood with exceptional sensitivity and detail. This capability allows the differentiation of phosphorylated tau protein from total phosphorylated tau protein in plasma, marking a pivotal development in the early detection and assessment of neurodegenerative disease risks, such as Alzheimer’s disease.

Addressing Inflammatory Mechanisms

Moreover, the NULISAseq 250 inflammatory panel empowers researchers to conduct complex and sensitive profiling of proteins tied to immunological factors that play roles in aging and the neuroinflammatory responses associated with neurodegenerative diseases. The resulting proteomic data will be harmonized with extensive clinical, demographic, and imaging datasets, facilitating researchers in tracking protein changes over time, identifying early biomarkers, and promoting the development of precise diagnostics and targeted therapies.

Dr. Yuling Luo, Founder, President, and CEO of Alamar Biosciences, elated about the collaboration, mentioned, “This partnership marks a significant step forward in aging and dementia research. With the unmatched sensitivity of NULISA and the rigor of DZNE’s Rhineland study, we can uncover novel protein biomarkers that reveal insights into cognitive health and disease progression in aging populations.”

Commitment to Scientific Rigor and Innovation

This collaboration reflects a shared commitment to rigorous scientific inquiry, inclusivity, and innovation in neurodegenerative disease research. By capturing diverse aging patterns in a well-characterized population, Alamar and DZNE aspire to expedite diagnostics, improve prognostics, and develop new therapeutic pathways for age-related brain disorders.

About DZNE

The DZNE Rhineland Study represents a widespread population-based cohort study observing thousands of individuals over decades to determine factors influencing healthy aging and neurodegeneration. Detailed clinical, imaging, genetic, and lifestyle data is amassed and harmonized to provide in-depth insights into the processes of brain aging. For more information on DZNE, visit www.dzne.de/en/, and for details on the Rhineland Study, explore www.rheinland-studie.de/en/.

About Alamar Biosciences

Alamar Biosciences is a private life sciences company committed to designing solutions for targeted proteomics aimed at the earliest disease detection. Its proprietary NULISA platform and ARGO HT system harness the latest advancements in genomics, providing detection sensitivity at single-digit attomolar concentrations, far exceeding existing top-tier protein detection technologies. More information can be found at alamarbio.com.